Expensify, Inc.
NASDAQ:EXFYSoftware - Application
+$0.35 today
- Market cap
- $157.19M
- Beta
- 1.80
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.22
Volume 0.63M
Average 0.79M
EXFY Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Expensify, Inc.NASDAQ: EXFY
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$28K, compared with $53K a year earlier. Trailing-twelve-month accounts receivables was -$436K. Over 3 fiscal years it compounded at -35.8% a year.
Context
- Accounts receivables amounted to 0.2% of revenue in FY2025, down 0.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$28K or moves back toward the trailing-twelve-month quarterly average of -$109K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (355K) USD
- Year-over-year change
- -150.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (355K) | -150.4% |
| FY2024 | 2024-12-31 | 704K | -68.3% |
| FY2023 | 2023-12-31 | 2.22M | +265.5% |
| FY2022 | 2022-12-31 | (1.34M) | +75.3% |
| FY2021 | 2021-12-31 | (5.42M) | — |
Accounts Receivables vs competitors
How EXFY compares with its peers on the latest reported figures
- EXFY's LTM Mar 2026 accounts receivables of $436K is the smallest of the 10 companies compared; the peer median is $1.48M.
- Its year-over-year change of -170.6% is the lowest of 10, against a peer median of -12.5%.
- Accounts receivables amounts to 0.3% of revenue for EXFY, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TEADTeads Holding Co. | LTM Mar 2026 | $46.94M | +8.9% | +69.9% | 3.7% |
| LTM Mar 2026 | $15.38M | -19.1% | — | 4.2% | |
| LTM Mar 2026 | $7.3M | +30.1% | -36.5% | 7.3% | |
| FY2025 | $6.4M | +219.4% | +828.4% | 37.4% | |
| LTM Mar 2026 | $3.94M | -12.5% | +29.7% | 21.2% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $3.73M | -45.0% | -53.6% | 5.6% |
| LTM Mar 2026 | $2.6M | +143.0% | +86.0% | 16.1% | |
| LTM Mar 2026 | $1.61M | -51.1% | — | 0.9% | |
HITHealth In Tech, Inc. | LTM Mar 2026 | $1.48M | -44.1% | +50.4% | 4.3% |
| LTM Mar 2026 | $436K | -170.6% | -35.8% | 0.3% | |
| Peer median (excluding EXFY) | $1.48M | -12.5% | +50.4% | 5.6% | |
Competitors are the stored peer set for EXFY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.56M) | (27.01M) | (41.46M) | (10.06M) | (21.39M) |
| Depreciation & Amortization | 5.2M | 5.39M | 5.16M | 6.81M | 8.46M |
| Deferred Income Tax | (868K) | 26K | (113K) | (42K) | 5K |
| Stock-Based Compensation | 14.57M | 52.33M | 41.21M | 33.54M | 26.58M |
| Change in Working Capital | (951K) | 550K | (5.04M) | (7.71M) | 5.12M |
| Accounts Receivables | (5.42M) | (1.34M) | 2.22M | 704K | (355K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | (2.69M) | 228K | (1.09M) | 91K |
| Other Working Capital | 3.05M | 4.58M | (7.49M) | (7.32M) | 5.39M |
| Other Non-Cash Items | 1.09M | 1.59M | 1.79M | 1.33M | 1.31M |
| Operating Cash Flow | 5.49M | 32.88M | 1.56M | 23.88M | 20.09M |
| Capital Expenditures | (7.61M) | (2.2M) | (7.29M) | (7.63M) | (17K) |
| Acquisitions (Net) | 0 | 5K | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (4.91M) | 0 | (5.91M) | 0 | (3.54M) |
| Investing Cash Flow | (7.61M) | (2.2M) | (7.29M) | (7.63M) | (3.56M) |
| Debt Repayment | 19.04M | (1.39M) | (45.1M) | (22.8M) | (140K) |
| Common Stock Issued | 58.03M | 3.67M | 4.26M | 4.09M | 6.64M |
| Common Stock Repurchased | 0 | (6.03M) | (3.02M) | (1.55M) | (9.1M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.51M | (5.34M) | (1.46M) | (1.82M) | (153K) |
| Financing Cash Flow | 80.57M | (8.28M) | (45.32M) | (22.07M) | (2.74M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.44M | 22.4M | (51.05M) | (5.82M) | 13.79M |
| Free Cash Flow | (2.13M) | 30.67M | (5.74M) | 16.25M | 20.07M |
Expensify, Inc.
NASDAQ:EXFY
Intrinsic Alpha fair value
Locked
Current Price
$1.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.